22-Oxovincaleukoblastine

• Antineoplastic Agents
• ATC:L01CA02

• 22-Oxovincaleukoblastine
• Indole alkaloid
• LCR
• Leurocristine
• Onco TCS
• Oncovin
• Oncovin (1:1 sulfate salt)
• VCR
• VIN
• Vincaleukoblastine, 22-oxo-
• Vincasar (1:1 sulfate salt)
• Vincasar PFS
• Vincrex
• Vincrex (1:1 sulfate salt)
• Vincristina [DCIT]
• Vincristine Sulfate
• Vincristine Sulfate PFS
• Vincristinum [INN-Latin]
• Vincrstine
• Vincrystine
• Vinkristin
• Z-D-Val-Lys(Z)-OH

• No information avaliable

C₄₆H₅₆N₄O₁₀

http://www.rxlist.com/cgi/generic3/vincristine.htm

http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=35

22-Oxovincaleukoblastine MSDS

No information avaliable

824.958 g/mol

220 ^oC

No information avaliable

Solid

4.918

Liquid; Solution

For treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, acute panmyelosis

Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.

No information avaliable

IVN-RAT LD₅₀ 1300 mg/kg; IPR-MUS LD₅₀ 5.2 mg/kg

PATIENT INFORMATION

Follow the links

http://www.rxlist.com/cgi/generic3/vincristine_wcp.htm

http://www.drugs.com/cons/Vincristine.html

Humans and other mammals